8-K: Precigen Reports Full Year 2024 Financial Results and Business Updates; Highlights FDA Priority Review for PRGN-2012

Precigen announces its full year 2024 financial results, highlighting FDA priority review for PRGN-2012 and extending its cash runway into 2026.

Summary

• Precigen reported its full year 2024 financial results and provided business updates.
• The FDA granted priority review to the company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis (RRP), with a PDUFA target action date set for August 27, 2025.
• Pivotal clinical study results of PRGN-2012 were published in The Lancet Respiratory Medicine, demonstrating durable complete responses with a median duration of two years.
• The company ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending its cash runway into 2026.
• Total revenues decreased by $2.3 million, or 37%, compared to the year ended December 31, 2023, primarily due to reductions in product and service volumes at Exemplar.
• Research and development expenses increased by $4.5 million, or 9%, compared to the year ended December 31, 2023, driven by the PRGN-2012 confirmatory clinical trial and manufacturing costs.
• Net loss was $126.2 million, or $(0.47) per basic and diluted share, compared to a net loss of $95.9 million, or $(0.39) per basic and diluted share, in the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the FDA priority review for PRGN-2012 and the extended cash runway, offset by revenue decline and net losses.

Positives

• FDA granted priority review for PRGN-2012, accelerating its potential approval.
• PRGN-2012 demonstrated strong clinical results in RRP patients, with durable complete responses and reduced need for surgeries.
• The company has extended its cash runway into 2026, providing financial stability for ongoing operations and potential commercial launch of PRGN-2012.
• Successful fundraising activities in December 2024 strengthened the company's financial position.
• The market opportunity for PRGN-2012 in RRP is estimated to be approximately 27,000 adult patients in the US and more than 125,000 patients outside of the US.

Negatives

• Total revenues decreased by 37% compared to the prior year, primarily due to lower product and service volumes at Exemplar.
• The company recorded a net loss of $126.2 million for the year ended December 31, 2024, which is higher than the net loss of $95.9 million in the previous year.
• Impairment charges related to Exemplar and ActoBio operations negatively impacted the company's financial results.
• Research and development expenses increased, driven by the PRGN-2012 confirmatory clinical trial and manufacturing costs.

Risks

• The company's future success depends heavily on the successful development and commercialization of PRGN-2012.
• Regulatory approval of PRGN-2012 is not guaranteed, and the FDA could require additional clinical trials or data.
• The company faces competition from other companies developing treatments for RRP and other diseases.
• The company's financial results could be negatively impacted by future impairment charges or other unforeseen events.
• The company is preparing for an end of Phase 1b meeting with the FDA to discuss next steps for PRGN-3006 in acute myeloid leukemia (AML).

Future Outlook

The company anticipates a potential 2025 commercial launch of PRGN-2012 and expects to transition from a clinical to commercial stage company, potentially adding product-related revenue.

Management Comments

• Helen Sabzevari, PhD, President and CEO of Precigen, stated that the company achieved several milestones on its path to potentially bring PRGN-2012 to RRP patients.
• Harry Thomasian Jr., CFO of Precigen, mentioned that the company extended its cash runway into 2026 as a result of the preferred stock offering and sale of intellectual property.

Industry Context

Precigen is focused on gene and cell therapies, a rapidly growing area in the biopharmaceutical industry. The potential approval of PRGN-2012 would position the company as a leader in the treatment of RRP.

Comparison to Industry Standards

• The median duration of response of two years for PRGN-2012 in RRP patients is a significant improvement compared to existing treatments, which primarily focus on surgical removal of papillomas.
• Companies like BioCryst Pharmaceuticals, which markets Orladeyo for hereditary angioedema, and Vertex Pharmaceuticals, known for its cystic fibrosis treatments, have successfully transitioned from clinical to commercial stage with FDA-approved therapies.
• Precigen's cash runway into 2026 provides a competitive advantage compared to smaller biotech companies that often face funding challenges.

Stakeholder Impact

• Shareholders may benefit from the potential commercial success of PRGN-2012 and the company's strengthened financial position.
• Patients with RRP could have access to a new and effective treatment option.
• Employees are impacted by workforce reductions and the suspension of ActoBio's operations.

Next Steps

• The company will continue to advance its commercial and manufacturing readiness campaign in anticipation of a potential launch of PRGN-2012 in 2025.
• Patient enrollment continues to advance in the confirmatory clinical trial of PRGN-2012.
• The Company is preparing for an end of Phase 1b meeting with the FDA to discuss next steps for PRGN-3006 in acute myeloid leukemia (AML).

Key Dates

Keywords

PRGN-2012, recurrent respiratory papillomatosis, RRP, gene therapy, financial results, FDA, biopharmaceutical, Precigen